TickerFiles

Autolus Therapeutics plc

Nasdaq · CIK 0001730463 · Fiscal year end 1231

AUTL

Latest reported period: Latest published period

Revenue

$26.2M

Cost Of Revenue

$24.6M

Operating Income

$-59.5M

Recent financials

MetricCurrentPriorChange
Revenue$26.2M--
Cost Of Revenue$24.6M--
Operating Income$-59.5M--
Net Income$-71.6M--
Eps Basic-0.27--
Eps Diluted-0.27--
Cash And Equivalents$130.9M--
Total Assets$527.1M--
Total Liabilities$418.2M--
Shareholders Equity$108.8M--
Operating Cash Flow$-65.3M--
Capital Expenditures$2.7M--

Latest filings

FormCompanyFiledAccession
10-QAutolus Therapeutics plc2026-05-140001730463-26-000065
10-KAutolus Therapeutics plc2026-03-270001730463-26-000038
10-QAutolus Therapeutics plc2025-11-120001730463-25-000088
10-QAutolus Therapeutics plc2025-08-120001730463-25-000067